Evaluating only BioMX’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
BioMX spun out of Weizmann Institute in Rehovot to commercialize phage-based microbiome treatments.
FUNDING
Raised $21M Series B to advance BX004 acne phage therapy into Phase 2 clinical trials.
PRODUCT LAUNCH
Phase 2 trial results for BX004 showed insufficient efficacy compared to placebo arm.
SHUTDOWN
All clinical programs halted; company wound down and returned remaining capital to shareholders.
Full Analysis
Free · no account needed
Documented cause
BioMX, spun out of the Weizmann Institute and led by CEO Jonathan Solomon, raised $46M to develop phage-based microbiome therapies targeting inflammatory diseases and acne. After Phase 2 clinical trials for its lead acne treatment BX004 showed insufficient efficacy versus placebo in 2023, the company halted all clinical programs and announced closure in early 2024, returning remaining capital to shareholders.
Lesson
“Single-program biotech companies have binary outcomes; diversify clinical pipeline before Phase 2.”